Table 1 Baseline characteristics of patients enrolled in a pilot treatment program for chronic hepatitis B in Ethiopia, 2015
From: Five-year results of a treatment program for chronic hepatitis B in Ethiopia
All patients (n = 1303) | Started treatment (n = 291) | Not started treatment (n = 1012) | Significance (p) | |
|---|---|---|---|---|
Socio-demographic characteristics | ||||
Women | 533 (40.9) | 68 (23.4) | 465 (45.9) | < 0.001 |
Age, years | 31 (26–40) | 33 (27–41) | 30 (26–39) | 0.020 |
18–25 | 286 (21.9) | 60 (20.6) | 226 (22.3) | 0.078 |
26–35 | 549 (42.1) | 108 (37.1) | 441 (43.6) | |
36–45 | 289 (22.2) | 77 (26.5) | 212 (20.9) | |
> 45 | 179 (13.7) | 46 (15.8) | 133 (13.1) | |
Alcohol misuse | 45 (3.5) | 21 (7.2) | 24 (2.4) | < 0.001 |
Laboratory tests and liver fibrosis assessment | ||||
ALT, IU/La | 25 (19–37) | 36 (24–53) | 23 (18–33) | < 0.001 |
< 40 | 1014 (78.9) | 166 (57.0) | 848 (85.3) | < 0.001 |
40–79 | 201 (15.6) | 86 (29.6) | 115 (11.6) | |
≥ 80 | 70 (5.4) | 39 (13.4) | 31 (3.1) | |
HBV viral load, IU/mLb | 1285 (242–14,409) | 34,685 (760–8,766,203) | 875 (202–5522) | < 0.001 |
< 2000 | 785 (61.4) | 97 (33.3) | 688 (69.6) | < 0.001 |
2000–19,999 | 194 (15.2) | 41 (14.1) | 153 (15.5) | |
≥ 20,000 | 300 (23.5) | 153 (52.6) | 147 (14.9) | |
HBeAg positivec | 142 (12.1) | 85 (29.6) | 57 (6.5) | < 0.001 |
Co-infections | ||||
Anti-HCV positived | 29 (2.6) | 6 (2.2) | 23 (2.7) | 0.660 |
Anti-HDV positivee | 19 (1.5) | 11 (3.9) | 8 (0.8) | < 0.001 |
Transient elastography, kPaf | 5.9 (4.7–8.1) | 13.4 (8.4–27.4) | 5.3 (4.4–6.5) | < 0.001 |
< 8.0 | 889 (74.5) | 59 (21.4) | 830 (90.5) | < 0.001 |
8.0–9.9 | 68 (5.7) | 39 (14.1) | 29 (3.2) | |
≥ 10.0 | 236 (19.8) | 178 (64.5) | 58 (6.3) | |
APRI-scoreg | 0.24 (0.17–0.37) | 0.47 (0.27–0.86) | 0.21 (0.16–0.30) | < 0.001 |